AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical Pipeline to be featured at AACR
- Data to be Featured in Five Oral Presentations and Seven Poster Sessions -
CAMBRIDGE, MA April 12, 2007 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel, targeted cancer medicines, announced today that it will present a total of 12 oral and poster presentations at the American Association for Cancer Research (AACR) Annual Meeting on April 14-18, 2007, in Los Angeles, California.
“We are very excited to share with the cancer community the pioneering oncology research platform AVEO has developed, which we believe may significantly enhance the probability of success and the efficacy of the next generation of targeted cancer therapies,” said Tuan Ha-Ngoc, president and CEO of AVEO Pharmaceuticals. “AVEO is focusing on translating this groundbreaking science into new drugs that may have a significant impact on cancer patient care and more importantly, patient response and outcomes.”
These presentations focus on several applications of AVEO’s breakthrough Human Response Prediction™ Platform of in vivo inducible mouse models.
The abstracts selected for oral presentations at the AACR Annual Meeting are listed below:
- Saturday, April 14, 2007 at 9:00 a.m. to 9:20 a.m. “Response prediction in engineered models: Using natural variation in preclinical tumor populations to assess the genetic context of drug response” – Educational Session: Validating Therapeutic Targets: In Vivo Models and Clinical Responses – Concourse E
- Saturday, April 14, 2007 at 2:00 p.m. to 2:20 p.m. “Human-in-mouse tumors: Creating de novo human breast cancer in mice through ex vivo genetic manipulation of normal breast tissue” – Methods Workshop: Recent Advances in Mouse Models of Cancer – Concourse E
- Wednesday, April 18, 2007 at 10:40 a.m. to 10:55 a.m. “Comprehensive in vivo genetic screens for tumor maintenance pathways in solid tumor models by retroviral mutagenesis” – Mini-symposium: Integrated Genomic Analysis of Human Cancer – Room 304 A-C
- Wednesday, April 18, 2007 at 10:25 a.m. to 10:40 a.m. “A novel chimeric approach to modeling cancer in mice reveals that EGFR dependency in lung tumors is mediated through non canonical RTK-MAPK signaling” – Mini-symposium: Mouse Models of Cancer – Room 406 A-B
- Wednesday, April 18, 2007 at 10:40 a.m. to 10:55 a.m. “Genetically engineered human breast cancer in mouse (HIM): A novel cancer model system that progresses in vivo and exhibits phenotypic variations” – Mini-symposium: Mouse Models of Cancer – Room 406 A-B
The schedule for poster presentations at the AACR Annual Meeting is listed below:
- Monday, April 16, 2007 at 8:00 a.m. to 12:00 p.m. “Genetically engineered murine tumor models for drug response prediction: Population based pathway profiles predict response to repamycin in a HER2 driven breast model” – Poster Session: Mouse Models in Cancer – Section 23, Board 28
- Monday, April 16, 2007 at 1:00 p.m. to 5:00 p.m. “Directed complementation of inducible tumor models: An approach to generate broad panels of tumors with defined genetic contexts” – Poster Session: Mouse Models of Cancer – Section 22, Board 29
- Tuesday, April 17, 2007 at 8:00 a.m. to 12:00 p.m. “AV-412, a potent EGFR/HER2 TK inhibitor causes tumor regression in novel genetically engineered EGFRL858R and EGFRL858R and T790M lung tumor models” – Poster Session: EGFR Inhibition – Section 28, Board 6
- Tuesday, April 17, 2007 at 8:00 a.m. to 12:00 p.m. “A novel beta-Catenin dependent p53DN mouse model of colon cancer displays stage dependent expression of EGFR” – Poster Session: Mouse Models of Cancer – Section 20, Board 9
- Tuesday, April 17, 2007 at 8:00 a.m. to 12:00 p.m. “A chimeric mouse model of ovarian cancer driven by inducible expression of PI3K catalytic subunit (p110alpha)” – Poster Session: Mouse Models of Cancer – Section 21, Board 4
- Tuesday, April 17, 2007 at 8:00 a.m. to 12:00 p.m. “Novel human basal type breast cancer models generated through genetic manipulation of normal human breast tissue in mice” – Poster Session: Mouse Models of Cancer – Section 21, Board 8
- Tuesday, April 17, 2007 at 1:00 p.m. to 5:00 p.m. “In vivo genetic screens designed to complement loss of HER2 of kRas functions identify c-Met/HGF pathway as potent driver of growth/survival in solid tumor models” – Poster Session: Mouse Models of Cancer – Section 21, Board 8
AVEO is a private biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. The company utilizes its proprietary, genetically-defined cancer models for the identification and validation of novel cancer targets, and has begun to build an impressive portfolio of drug discovery and development programs around these high-value targets. AVEO also uses its Human Response Prediction™ Platform to identify genetic profiles that correspond with patient responsiveness. AVEO expects to commence Phase 2 clinical studies by mid-2007 for AV-951, its oral, second-generation VEGF receptor inhibitor and most advanced clinical program. AV-412, AVEO’s EGFR/HER2 inhibitor, is currently in Phase I clinical trials. AV-299, a novel anti-HGF mAb, is currently being manufactured by XOMA under a supply agreement in anticipation of entering the clinic in early 2008. AVEO is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.aveopharma.com.